ABMD 33.55 Abiomed $ABMD Hit a 52 week high of 34.04

New Post Public Reply Private Reply Replies (0) Message Board

Nov 18, 2014 at 10:07 AM

ABMD 33.55 Abiomed $ABMD Hit a 52 week high of 34.04 Closing the day 09:44 at 33.55 -0.21 -0.62% With a day low of 33.55 and a total volume of 12,883.

ABMD Recent Posts: http://investorshangout.com/Abiomed-ABMD-53201/

ABMD Abiomed Recent Headline News

ABIOMED Earnings In Retrospect: Up 6.1% in the Last 18 Days (ABMD)
Comtex SmarTrend(R) - Mon Nov 17, 12:42PM CST
When ABIOMED (NASDAQ:ABMD) reported earnings 18 days ago on October 30th, 2014, analysts, on average, expected the company to report earnings of $0.02 on sales of $50.1 million. ABIOMED actually reported earnings of $0.09 per share on sales of $51.9 million, beating EPS estimates by $0.07 and beating revenue estimates by $1.8 million. Shares of ABIOMED have climbed from $31.35 to $33.25, representing a gain of 6.1% since the company reported earnings 18 days ago.
ABMD: 33.67 (-0.09)

Abiomed to Present at the Jefferies 2014 Global Healthcare Conference
GlobeNewswire - Mon Nov 17, 7:18AM CST
Abiomed, Inc. (Nasdaq:ABMD), a leading provider of breakthrough heart support technologies, today announced that Robert L. Bowen, Vice President & Chief Financial Officer, will present at the Jefferies 2014 Global Healthcare Conference on November 20, 2014 at 10:40 a.m. GMT. The conference will be held at The Waldorf Hilton London in London, UK.
ABMD: 33.67 (-0.09)

Varian Medical (VAR) Down to Strong Sell on Dismal Q3 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 14, 2:20PM CST
On Nov 14, 2014, Zacks Investment Research downgraded Varian Medical Systems (VAR) to a Zacks Rank #5 (Strong Sell).
ABMD: 33.67 (-0.09), VAR: 88.34 (+0.73), EW: 127.48 (+1.25), ANGO: 16.82 (-0.03)

ABIOMED (ABMD) Stock: Moving Average Crossover Alert - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Nov 13, 6:33AM CST
ABIOMED (ABMD) Stock: Moving Average Crossover Alert
ABMD: 33.67 (-0.09)

Thoratec (THOR) Down to Strong Sell on Growing Headwinds - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Nov 12, 12:20PM CST
On Nov 11, 2014, Zacks Investment Research downgraded Thoratec Corp. (THOR) to a Zacks Rank #5 (Strong Sell).
ABMD: 33.67 (-0.09), EW: 127.48 (+1.25), THOR: 30.20 (+1.00), ANGO: 16.82 (-0.03)

Abiomed (ABMD) Hits 52-Week High on Strong Q2 Results - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Nov 12, 10:10AM CST
Shares of Abiomed, Inc. (ABMD) have been on the rise since it reported impressive second-quarter fiscal 2015 (ended Sep 30, 2014) results on Oct 30.
ABMD: 33.67 (-0.09), FLDM: 30.68 (+0.67), GMED: 22.95 (+0.52), ANGO: 16.82 (-0.03)

ABIOMED Shares Up 34.3% Since SmarTrend's Buy Recommendation (ABMD)
Comtex SmarTrend(R) - Wed Nov 12, 9:15AM CST
SmarTrend identified an Uptrend for ABIOMED (NASDAQ:ABMD) on October 28th, 2014 at $24.67. In approximately 2 weeks, ABIOMED has returned 34.28% as of today's recent price of $33.13.
ABMD: 33.67 (-0.09)

Mettler-Toledo (MTD) Tops Q3 Earnings on Revenue Strength - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Nov 12, 8:34AM CST
Mettler-Toledo International Inc. (MTD) reported adjusted earnings per share (EPS) of $2.95 for the third quarter of fiscal 2014, which beat the Zacks Consensus Estimate of $2.86. Adjusted EPS also improved 13% from the year-ago quarter.
ABMD: 33.67 (-0.09), FLDM: 30.68 (+0.67), ANGO: 16.82 (-0.03), MTD: 291.48 (+2.51)

Roka Bioscience (ROKA) in Focus: Stock Surges 19.3% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Nov 11, 8:11AM CST
Roka Bioscience, Inc. (ROKA) was a big mover last session, as the company saw its shares rise over 19% on the day.
ABMD: 33.67 (-0.09), ROKA: 3.82 (+0.07), EW: 127.48 (+1.25), ANGO: 16.82 (-0.03)

OTC Daily Alert Stock Watch - ABIOMED, Inc. (NASDAQ: ABMD)
WorldStockWire - Mon Nov 10, 12:30PM CST
OTC Daily Alert tracks stocks daily and is pleased to offer features on public companies. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Daily Alert at the following: http://www.otcdailyalert.com
ABMD: 33.67 (-0.09)

Volcano Posts Narrower-than-Expected Q3 Loss, Guides Low - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 10, 10:10AM CST
Despite Volcano (VOLC) provided disappointing revenue guidance for 2014 on account of expected negative foreign exchange impact, management expects accelerated profitability over the near term.
ABMD: 33.67 (-0.09), VOLC: 11.30 (+0.22), EW: 127.48 (+1.25), ANGO: 16.82 (-0.03)

Strength Seen in DexCom (DXCM): Stocks Gains 14.1% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Nov 10, 8:46AM CST
DexCom (DXCM) was a big mover last session, with shares rising over 14% on the day.
ABMD: 33.67 (-0.09), DXCM: 52.50 (+0.76), EW: 127.48 (+1.25), ANGO: 16.82 (-0.03)

VYCOR: "On the Cusp of the Next Big Healthcare Trend"
ACCESSWIRE - Mon Nov 10, 8:23AM CST
Vycor: "On the Cusp of the Next Big Healthcare Trend"
MDVN: 107.92 (+1.12), ABMD: 33.67 (-0.09), JNJ: 108.78 (+0.48), AMGN: 159.61 (+0.47), EXAS: 23.13 (+0.17), ARAY: 6.96 (+0.14), HOLX: 26.52 (+0.15), PBYI: 216.00 (+4.45)

Update: Abiomed's Q2 Fiscal 2015 Earnings Remained Impressive
Andy Batts - at Seeking Alpha - Sat Nov 08, 4:40PM CST

ABMD: 33.67 (-0.09)

Hologic Beats Q4 Earnings, Sales as All Segments Gain - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 07, 1:50PM CST
Hologic (HOLX) entered into an amended license agreement with Roka Bioscience, which earned a one-time revenue benefit of $20.1 million for Hologic
ABMD: 33.67 (-0.09), DXCM: 52.50 (+0.76), ANGO: 16.82 (-0.03), HOLX: 26.52 (+0.15)

Thoratec Q3 Earnings & Revenues Lag Estimates, Down Y/Y - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 07, 9:00AM CST
Following the earnings release, shares of Thoratec Corp. (THOR) declined approximately 3.5% to close at $26.10 yesterday.
ABMD: 33.67 (-0.09), CYNO: 28.10 (+0.25), THOR: 30.20 (+1.00), ANGO: 16.82 (-0.03)

Abiomed (ABMD) Upgraded From Hold to Buy
at The Street - Fri Nov 07, 8:07AM CST
Abiomed (ABMD) has been upgraded by TheStreet Ratings from Hold to Buy with a ratings score of B.
ABMD: 33.67 (-0.09)

Foundation Medicine Slumps: FMI Tumbles 9.6% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Nov 07, 7:59AM CST
Foundation Medicine has been witnessing a flat trend in its current year earnings estimate and its share price has been falling for past 24 hours
ABMD: 33.67 (-0.09), DXCM: 52.50 (+0.76), FMI: 25.48 (+0.28), ANGO: 16.82 (-0.03)

Mindray Medical Q3 Earnings in Line, 2014 View Lowered - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 04, 2:07PM CST
Mindray Medical International Limited (MR) slashed its 2014 financial guidance in the face of increasing uncertainties in currency and other macro developments that could impact its performance in certain key markets.
ABMD: 33.67 (-0.09), FLDM: 30.68 (+0.67), ANGO: 16.82 (-0.03), MR: 31.16 (-0.06)

Abiomed Tops Q2 Earnings, Revenues; FY15 Sales View Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 04, 12:10PM CST
Abiomed Inc. (ABMD) reported second-quarter fiscal 2015 earnings of 9 cents per share, outshining the Zacks Consensus Estimate of 2 cents.
ABMD: 33.67 (-0.09), FLDM: 30.68 (+0.67), BEAT: 8.18 (+0.04), ANGO: 16.82 (-0.03)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Steady Income Boosts FHLBank Boston's Growth Q3 2026

The Federal Home Loan Bank of Boston dropped their third-quarter results for 2026 like a hot smokestack, and let me tell you, it's a mixed bag of cautious optimism and steady progression. It's essentially proof that slow and steady might just win the race—or at least keep you in the running. Stable and Steady Headway Taking a peek under the hood, FHLBank Boston made a...

Podcast Giants Converge in Tennessee for POD U Summit

Nashville Becomes a Hotspot for Podcasters Amidst the strumming guitars and honky-tonk vibes of Nashville, Tennessee transformed into the epicenter of podcasting innovation thanks to Rebel Audio's inaugural summit, POD U. Here we had big names like Mike 'Big Mike' Majlak rubbing shoulders with sports experts and media moguls—a true concoction of voices shaping the...

Dimora Medical Boosts Advanced Wound Care at HS Conference

Empowering the HS Community with Innovations Look, if you’ve walked a mile in someone else's shoes—particularly ones dealing with hidradenitis suppurativa (HS)—you’d know what a relentless grind managing those exuding wounds can be. Dimora Medical, known for navigating the tricky territory of wound care, threw its hat into the ring at the HS Connect Empower...

Amy Johnson Steps Up as GDIT President Amid Shifts

A New Chapter for GDIT with a Veteran Leader Big shoes to fill? Nah, more like Amy Johnson was made for these shoes. Stepping up as president of General Dynamics Information Technology (GDIT) on November 3, she’s got 27 years of experience under her belt, all from General Dynamics' own backyard. This ain't her first rodeo. From tightrope-walking the perils of defense...

Bio-Thera's New Data: A Game Changer for NSCLC?

A Fresh Look at Lung Cancer Solutions There's fresh meat on the oncology block, with Bio-Thera Solutions swinging for the fences at ESMO 2026, spotlighting promising Phase 2 clinical data for their combo treatment in first-line non-small cell lung cancer (NSCLC). If you're tuned into the biopharmaceutical sector or just keeping tabs on global health romps, this news sets...

Cowfest 2026 Delighted by Frederick's Flying Cows

Moo-ving Towards a New Record Alright, listen up. This fall, there's a bovine spectacle coming to Maryland that's more than just a trip down to the fairgrounds—it's Cowfest 2026, baby! Now, if you're scratching your head thinking this is just another seasonal shindig, you're underestimating what's mooing across Frederick County. The Flying Cows are ready to take the...

Gemmy's Orchestra of Lights Op. 2 Unveils New Show

Jazzing Up the Holidays with Gemmy's Latest Innovation Just when you thought holiday displays couldn't get more extravagant, along comes Gemmy with its latest wonder—the Orchestra of Lights™ Op. 2. Exclusively hitting Lowe's shelves, this isn't your average set of twinkling bulbs. It's an all-out sensory assault, mixing tunes straight out of yuletide hit lists with...

Hyperliquid Expands Stock Buyback to $100 Million

Diving Into Hyperliquid's $100 Million Bold Move Let’s cut through the corporate fluff—Hyperliquid Strategies Inc. just cranked up their stock repurchase program to a cool $100 million. Yep, that’s right—the brain trust behind NASDAQ:PURR has pulled out the checkbook to buy more of its own shares. This decision, unveiled on October 23, 2026, is like tossing a...

A Game-Changer for Pediatric Diabetes: Novo's Awiqli®

Breaking Through the Diabetes Treatment Wall From where I'm sitting, breakthrough approvals like Novo's Awiqli® hit the healthcare landscape with all the subtlety of a freight train. The FDA's green light for Awiqli® as the first once-weekly insulin for kids aged 10 and over with type 2 diabetes is a monumental shift in the treatment paradigm. We're talking about...

Violet PR's Big Wins Hint at Industry Strategies

A Shining Night in Morristown Picture Violet PR's team on top of the world, right there in Morristown, getting the accolades every agency dreams of—five awards from PRSA-NJ. It's not just an ego trip, either. This is about setting a high bar in the world of strategic communications, and they're flaunting their ability to drive growth and innovation in the economic...